Yong Dai, Frontera Therapeutics CEO

Scoop: Lit­tle-known Or­biMed-backed biotech clos­es $160M round to start gene ther­a­py tri­al

Fron­tera Ther­a­peu­tics, a Chi­na and US biotech, has closed a $160 mil­lion Se­ries B and re­ceived reg­u­la­to­ry clear­ance to test its first gene ther­a­py state­side …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.